Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,740 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,740 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Aug 9, 2021 | City of Hope Medical Center | no accrual | Enrollment / accrual |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and…(ULTRA-V) | Phase 2 / Phase 3 | terminated | Jan 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT02661022 | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and… | Phase 1 / Phase 2 | terminated | Jan 21, 2016 | Stemline Therapeutics, Inc. | not stated | Not stated |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT00893516 | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | Phase 2 | terminated | May 6, 2009 | Emergent BioSolutions | Portfolio consolidation. | Sponsor / business decision |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT…(AHCT) | Early Phase 1 | withdrawn | Aug 19, 2021 | Koen van Besien | The original principal Investigator left the institution. | Investigator |
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Phase 1 / Phase 2 | terminated | Sep 20, 2017 | Poseida Therapeutics, Inc. | Phase I portion of the study was completed. The phase II portion of the study was terminated early… | Other (stated, no rule matched) |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects… | Phase 2 | terminated | Feb 21, 2021 | Epizyme, Inc. | Decision to terminate EZH-1401 was solely due to company business decision. | Sponsor / business decision |
| NCT03571828 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in… | Phase 1 | terminated | Jun 28, 2018 | Amgen | Amgen decided to discontinue study because of a business decision and not because of safety reasons | Safety / toxicity |
| NCT04668768 | HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and… | Phase 2 | suspended | Dec 16, 2020 | Fox Chase Cancer Center | To be terminated due to slow accrual, patient still in follow up | Enrollment / accrual |
| NCT04115059 | Dasatinib In Waldenström Macroglobulinemia | Phase 1 | terminated | Oct 3, 2019 | Jorge J. Castillo, MD | Lack of efficacy | Efficacy / futility |
| NCT05711628 | A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab)… | Phase 3 | withdrawn | Feb 3, 2023 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04083898 | Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | Phase 1 | terminated | Sep 10, 2019 | Washington University School of Medicine | Decision made to not move forward with Phase II portion of trial | Other (stated, no rule matched) |
| NCT03473496 | CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma(MM) | N/A | terminated | Mar 22, 2018 | Zhujiang Hospital | After CAR-T treatment, the benefit is not significant, and it is difficult to enroll. | Enrollment / accrual |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | Phase 2 | terminated | May 21, 2015 | Swiss Cancer Institute | The premature termination is based on the decision by the SAKK board on November 14, 2020 due to… | Funding |
| NCT02700841 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | Phase 2 | terminated | Mar 7, 2016 | University of Nebraska | Study terminated prematurely due to poor recruitment. | Enrollment / accrual |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40… | Phase 1 / Phase 2 | terminated | Dec 7, 2023 | GlaxoSmithKline | The study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT02282358 | Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in… | Phase 1 / Phase 2 | terminated | Nov 4, 2014 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04144140 | Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766… | Phase 1 | terminated | Oct 30, 2019 | Eisai Inc. | The study was terminated earlier due to a business decision; which was unrelated to safety. In… | Safety / toxicity |
| NCT04509466 | Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With… | Phase 1 / Phase 2 | terminated | Aug 12, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT04548700 | Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and… | Phase 1 | terminated | Sep 14, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT06104878 | A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With… | — | withdrawn | Oct 27, 2023 | Takeda | Company decision after projects re-evaluation, taken before the study initiation | Sponsor / business decision |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04920383 | ALPN-202 With PD-1 Inhibition in Advanced Malignancies(NEON-2) | Phase 1 | terminated | Jun 9, 2021 | Alpine Immune Sciences, Inc. | Sponsor decision | Sponsor / business decision |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
| NCT03357224 | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)(PARCT) | Phase 2 | terminated | Nov 29, 2017 | European Organisation for Research and Treatment of Cancer - EORTC | Following an urgent safety measure due to toxicity recruitment has been closed prematurely. | Safety / toxicity |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell… | Phase 1 / Phase 2 | terminated | Nov 10, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With… | Phase 1 | terminated | Dec 7, 2022 | Anaveon AG | The study was ended due to a lack of recruitment | Enrollment / accrual |
| NCT04912427 | Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe… | Phase 1 | terminated | Jun 3, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell… | Phase 1 / Phase 2 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | Administrative decision | Other (stated, no rule matched) |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell… | Phase 1 | withdrawn | Jul 10, 2020 | Fred Hutchinson Cancer Center | NIH terminated funding. Study was closed before any participants were enrolled. | Enrollment / accrual |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients…(OCEAN) | Phase 3 | terminated | May 12, 2017 | Oncopeptides AB | Sponsor assessed all endpoints and collected Overall Survival data for another two years following… | Other (stated, no rule matched) |
| NCT04609579 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Phase 1 | terminated | Oct 30, 2020 | Stingthera, Inc. | Sponsor decision (not due to safety concerns) | Safety / toxicity |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer… | Phase 2 | terminated | Jul 10, 2020 | OHSU Knight Cancer Institute | Insufficient accrual rate | Enrollment / accrual |
| NCT02031419 | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell… | Phase 1 | terminated | Jan 9, 2014 | Celgene | Replaced with another clinical trial. | Other (stated, no rule matched) |
| NCT03495713 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR… | Phase 2 | terminated | Apr 12, 2018 | Abramson Cancer Center at Penn Medicine | Covid-19 | COVID-19 / pandemic |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | suspended | Aug 10, 2020 | NexImmune Inc. | Lack of accrual | Enrollment / accrual |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the… | Phase 2 | withdrawn | Jan 7, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in…(CheckMate 812) | Phase 3 | terminated | May 3, 2017 | Bristol-Myers Squibb | Insufficient enrollment. | Enrollment / accrual |
| NCT03502577 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat… | Phase 1 | terminated | Apr 18, 2018 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT03657251 | MMRF CureCloud Research Initiative | — | terminated | Sep 5, 2018 | Multiple Myeloma Research Foundation | The MMRF has learned of the limitations of using a blood sample to collect genomic data, compared… | Other (stated, no rule matched) |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell… | Phase 1 | terminated | Mar 6, 2019 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201… | Phase 1 | withdrawn | Aug 8, 2023 | The First Affiliated Hospital of Soochow University | Molecular development strategy adjustment | Sponsor / business decision |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab… | Phase 3 | terminated | Sep 16, 2020 | GlaxoSmithKline | The study has been terminated for reasons pertaining to feasibility | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Apr 25, 2024source: clinicaltrials